FORM 4

Γ

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

or Tuno D

Washington, D.C. 20549 OMB Numb

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Find of Type Kespo	(11505)										
1. Name and Addres GENERAL HILI	2. Issuer Name and Ticker or Trading Symbol iBio, Inc. [IBPM.OB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10%Owner				
(Last) C/O IBIOPHARM INNOVATION	3. Date of Earliest Transaction (Month/Day/Year) 08/16/2010							Other (s			
NEWARK, DE 1		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)		Table I - Non-Derivative Securities Acqui						ired, Disposed of, or H	Beneficially (Owned	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execu any	Deemed ttion Date, if th/Day/Year)	3. Transact Code (Instr. 8 Code	tion	4. Securi Acquired Disposed (Instr. 3, Amount	l (A) d of (I 4 and (A) or))	Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial Ownership

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of

SEC 1474 (9-02)

currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative	2. Conversion		3A. Deemed Execution Date, if	4. Transac					7. Title and Amount of Underlying		8. Price of 9 Derivative I		10. Ownership	11. Nature of Indirect	
Security	or Exercise	(Month/Day/Year)	any	Code	de Derivative		(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securities				(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquired							-	(Instr. 4)	
	Security					(A) or					0	Direct (D)			
						Disposed of					1	or Indirect			
						(D)							Transaction(s)	· · /	
					(Instr. 3, 4,		, 4,						(Instr. 4)	(Instr. 4)	
					and 5)										
											Amount				
								Date	Expiration	T. 4	or				
								Exercisable	Date		Number				
				Code	v	(A)	(D)				of Shares				
~ .				Couc	v	(A)	(D)				Shares				
Stock															
Option	\$ 1.73	08/16/2010		А		30,000		<u>(1)</u>	08/16/2020	Common Stock	30,000	\$0	30,000	D	
(right to	φ1.75	00/10/2010		71		50,000			00/10/2020	Stock	50,000	ψŪ	50,000	D	
buy)															

information contained in this form are not

required to respond unless the form displays a

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GENERAL HILL (Ret) JAMES T. C/O IBIOPHARMA, INC. 9 INNOVATION WAY, SUITE 100 NEWARK, DE 19711	Х						

Signatures

/s/ General James T. Hill	09/09/2010
-Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in three equal annual installments beginning on July 1, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.